Diagnostic accuracy of 3 urine lipoarabinomannan tuberculosis assays in HIV-negative outpatients

• Verfasst von: Broger, Tobias [VerfasserIn]
• Verfasst von: Nicol, Mark P. [VerfasserIn]
• Verfasst von: Sigal, George B. [VerfasserIn]
• Verfasst von: Gotuzzo, Eduardo [VerfasserIn]
• Verfasst von: Zimmer, Alexandra J. [VerfasserIn]
• Verfasst von: Surtie, Shireen [VerfasserIn]
• Verfasst von: Caceres-Nakiche, Tatiana [VerfasserIn]
• Verfasst von: Mantsoki, Anna [VerfasserIn]
• Verfasst von: Reipold, Elena Ivanova [VerfasserIn]
• Verfasst von: Székely, Rita [VerfasserIn]
• Verfasst von: Tsionsky, Michael [VerfasserIn]
• Verfasst von: Heerden, Judith van [VerfasserIn]
• Verfasst von: Plisova, Tatiana [VerfasserIn]
• Verfasst von: Chikamatsu, Kinuyo [VerfasserIn]
• Verfasst von: Lowary, Todd L. [VerfasserIn]
• Verfasst von: Pinter, Abraham [VerfasserIn]
• Verfasst von: Mitarai, Satoshi [VerfasserIn]
• Verfasst von: Moreau, Emmanuel [VerfasserIn]
• Verfasst von: Schumacher, Samuel G. [VerfasserIn]
• Verfasst von: Denkinger, Claudia M. [VerfasserIn]
• Titel: Diagnostic accuracy of 3 urine lipoarabinomannan tuberculosis assays in HIV-negative outpatients
• Verf.angabe: Tobias Broger, Mark P. Nicol, George B. Sigal, Eduardo Gotuzzo, Alexandra J. Zimmer, Shireen Surtie, Tatiana Caceres-Nakiche, Anna Mantsoki, Elena Ivanova Reipold, Rita Székely, Michael Tsionsky, Judith van Heerden, Tatiana Plisova, Kinuyo Chikamatsu, Todd L. Lowary, Abraham Pinter, Satoshi Mitarai, Emmanuel Moreau, Samuel G. Schumacher, and Claudia M. Denkinger
• E-Jahr: 2020
• Jahr: July 21, 2020
• Umfang: 9 S.
• Fussnoten: Gesehen am 26.04.2021
• Titel Quelle: Enthalten in: The journal of clinical investigation
• Ort Quelle: Ann Arbor, Mich. : ASCJ, 1924
• Jahr Quelle: 2020
• Band/Heft Quelle: 130(2020), 11, Seite 5756-5764
• ISSN Quelle: 1558-8238
• DOI: doi:10.1172/JCI140461
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1755913885

Abstract

Background: Inadequate tuberculosis (TB) diagnostics are a major hurdle in the reduction of disease burden, and accurate point-of-care tests (POCTs) are urgently needed. We assessed the diagnostic accuracy of Fujifilm SILVAMP TB lipoarabinomannan (FujiLAM) POCT for TB diagnosis in HIV-negative outpatients and compared it with Alere Determine TB LAM Ag (AlereLAM) POCT and a laboratory-based ultrasensitive electrochemiluminescence LAM research assay (EclLAM). Methods: In this multicenter diagnostic test accuracy study, we recruited HIV-negative adults with symptoms suggestive of pulmonary TB presenting to outpatient health care centers in Peru and South Africa. Urine samples were tested using FujiLAM, AlereLAM, and EclLAM, and the diagnostic accuracy was assessed against a microbiological reference standard (MRS) and a composite reference standard. Results: Three hundred seventy-two HIV-negative participants were included and the prevalence of microbiologically confirmed TB was 30%. Compared with the MRS, the sensitivities of AlereLAM, FujiLAM, and EclLAM were 10.8% (95% confidence interval [CI] 6.3%–18.0%), 53.2% (95% CI 43.9%–62.1%), and 66.7% (95% CI 57.5%–74.7%), respectively. The specificities of AlereLAM, FujiLAM, and EclLAM were 92.3% (95% CI 88.5%–95.0%), 98.9% (95% CI 96.7%–99.6%), and 98.1% (95% CI 95.6%–99.2%), respectively. Positive likelihood ratios of AlereLAM, FujiLAM, and EclLAM were 1.4, 46.2, and 34.8, respectively, and positive predictive values were 37.5%, 95.2%, and 93.7%, respectively. Conclusion: Compared with AlereLAM, FujiLAM detected 5 times more patients with TB in HIV-negative participants, had a high positive predictive value, and has the potential to improve rapid diagnosis of TB at the point-of-care. EclLAM demonstrated that additional sensitivity gains are possible, which highlights LAM’s potential as a biomarker. Additional research is required to assess FujiLAM’s performance in prospective cohorts, its cost-effectiveness, and its impact in real-world clinical settings.